PART B - FEE(S) TRANSMITTAL

MAR 2 1 2006 Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 (571)-273-2885

or Fax

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEB and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the Fec(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. CURRENT CORRESPONDENCE ADDRESS (Note: Uso Block I for may change of address) 7590 02/16/2006 23914 Certificate of Meiling or Transmission

I hereby certify that this Fec(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class until in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. LOUIS J. WILLE BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT P O BOX 4000 Wojcik Debra A. PRINCETON, NJ 08543-4000 Werk (Signature מילעני (Date March 21 2006 CONFIRMATION NO. ATTORNEY DOCKET NO . _ . _ . FIRST NAMED INVENTOR __ ... -, FILING DATE APPLICATION NO. PH 7464 NP Bryan W. King 10/03/2003 10/678.331 TITLE OF INVENTION: TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR THE-ALPHA CONVERTING ENZYME DATE DUE PUBLICATION FEE TOTAL FEE(S) DUE ISSUE PEE SMALL ENTITY APPLN, TYPE 05/16/2006 \$1700 \$300 NO \$1400 nonprovisional ART UNIT CLASS-SUBCLASS EXAMINER 1626 514-340000 LAMBKIN, DEBORAH C Change of correspondence address or indication of "Fee Address" (37 CFR 1363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively. ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. Tree Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filled for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. a substitute for bling an assignment § 03/21/2006 HDEMESS2 00000031 193880 (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE 08543 01 FC:1501 1400.00 DA Bristol-Myers Squibb Company Princeton, NJ 300.00 DA 02 FC:1504 Reel/Frame: 014255/0682 O3 FC:8001 30.00 PA Government Please check the appropriate assignee category or categories (will not be printed on the patent): -4b.-Payment of Fee(s): 40. The following focts fire enclosed: A check in the amount of the fee(s) is enclosed. 🔀 Issue Fee Payment by credit card. Form PTO-2038 is stached. Publication Fee (No small entity discount permitted) The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 19-3880. (enclose an extra copy of this form). Advance Order - # of Copies 5. Change in Entity Status (from status indicated above) ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above, NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature

Jing Typed or printed name

Registration No.


This collection of information is required by 37 CFR 1.31). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including guthering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Parent and Trademark Office, U.S. Parent and Trademark Of

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB compol number.

BEST AVAILABLE COPY

10678331





Bristol-Myers Squibb Company Patent Department

DATE: March 21, 2006

FACSIMILE TRANSMITTAL SHEET

URGENT

TO:

USPTO - Issue Fee Branch

FAX NO.:

(571) 273-2885

FROM:

Jing G. Sun, Ph.D.

TELEPHONE NO.:

(609) 252-3791

FACSIMILE NO.:

(609) 252-4526

RE:

U.S. Application Serial No.: 10/678,331

Attorney Docket No.: PH7464 NP

Number of Pages:

3 (including cover sheet)

CERTIFICATE OF TRANSMISSION VIA FACSIMILE

I hereby certify that this correspondence, a 1) Issue Fee Transmittal (1 page); and 2) "Fee Address" Indication Form (1 page) are being facsimile transmitted to the U.S. Patent and Trademark Office, Fax number (571) 273-2885, on March 21, 2006.

ebra A. Wojcik/Depositor

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT(S) NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINITATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YO HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.